skin cancer
Castle Biosciences Receives NYS DOH Approval for Skin Cancer Diagnostic
The company's DecisionDx-SCC is meant to predict risk of cutaneous squamous cell carcinoma metastasis for patients with one or more risk factors.
The company said it is developing a new genomic test to predict therapeutic response in patients with inflammatory skin conditions.
Castle Biosciences Q1 Revenues Up 31 Percent
The company said it delivered 11 percent fewer DecisionDx-Melanoma test results year over year, but that the total number of all tests delivered rose 4 percent.
The firm's Q-plasia OncoReader Breast is the first in its line of products for different cancers, including skin, lung, and ovarian cancer.
Castle Biosciences Q4 Revenues Down 2 Percent
The skin cancer diagnostics company said it delivered 5 percent fewer DecisionDx-Melanoma test results in Q4 2020 than in the previous year's fourth quarter.
Mar 5, 2021
DermTech Q4 Revenues Up 31 Percent
Mar 9, 2020
Nov 11, 2019
Castle Biosciences Q3 2019 Revenues Quadruple
Sep 3, 2019
Castle Biosciences Q2 Revenues Up 168 Percent
Jul 25, 2019
Castle Bio Prices IPO at $16 per Share
Sep 26, 2018
Proscia Raises $8.3M in Series A Round
Jul 13, 2018
Apr 2, 2018
Feb 21, 2018
New York State Accredits DermTech
Oct 2, 2017
Jan 12, 2017